Name | trans-3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one |
---|---|
Synonyms | trans-3-(5-methoxy-2-methylindol-3-yl)-1-(4-pyridinyl)-2-propen-1-one |
Description | MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2]. |
---|---|
Related Catalog | |
In Vitro | MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1]. In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization[1]. MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2]. Western Blot Analysis[2] Cell Line: U251 cells Concentration: 10 μM Incubation Time: 4 h or 24 h Result: Activated the JNK stress kinase pathway. |
In Vivo | MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2]. Animal Model: Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks)[2] Dosage: 80 mg/kg Administration: i.p.; once daily; for 15 consecutive days Result: Suppressed progression of intracerebral glioblastoma xenografts. |
References |
Molecular Formula | C18H16N2O2 |
---|---|
Molecular Weight | 292.33 |
Exact Mass | 292.12100 |
PSA | 54.98000 |
LogP | 3.77600 |